Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma:A Phase II, Prospective, Multicenter, Single-Arm Clinical Study
Latest Information Update: 29 Jan 2026
At a glance
- Drugs Obinutuzumab (Primary) ; Orelabrutinib (Primary) ; Rituximab
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 29 Jan 2026 New trial record